Home » Stocks » RPHM

Reneo Pharmaceuticals, Inc. (RPHM)

Stock Price: $10.11 USD -0.62 (-5.78%)
Updated Jun 16, 2021 3:22 PM EDT - Market open
Market Cap 244.77M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 24.21M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 16
Last Price $10.11
Previous Close $10.73
Change ($) -0.62
Change (%) -5.78%
Day's Open 10.61
Day's Range 10.02 - 10.63
Day's Volume 52,325
52-Week Range 7.63 - 17.18

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN DIEGO, May 20, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients...

3 weeks ago - GlobeNewsWire

SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients...

4 weeks ago - GlobeNewsWire

Biotech stocks are making headlines on Friday as two companies join the public market via initial public offerings (IPOs) today. The post Biotech Stocks: 14 Things to Know as the VECT Stock IPO and RPHM...

Other stocks mentioned: VECT
2 months ago - InvestorPlace

SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, g...

2 months ago - GlobeNewsWire

Reneo Pharmaceuticals, a Phase 2 biotech developing therapies for rare genetic mitochondrial diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

2 months ago - NASDAQ

Reneo Pharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC

About RPHM

Reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo Pharmaceuticals is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. We are initially developing REN001 in three rare genetic diseases that typically present with myopathy and have high unmet medical nee... [Read more...]

Industry
Biotechnology
IPO Date
Apr 9, 2021
Stock Exchange
NASDAQ
Ticker Symbol
RPHM
Full Company Profile

Financial Performance

Financial Statements